






































BRIEF REPORT: CLINICAL SCIENCE
Drop in CD4+ Counts Below 200 Cells/mL After Reaching
(or Starting From) Values Higher than 350 Cells/mL
in HIV-Infected Patients With Virological Suppression
Nicola Gianotti, MD,* Giulia Marchetti, MD,† Andrea Antinori, MD,‡ Annalisa Saracino, MD,§
Andrea Gori, MD,k Giuliano Rizzardini, MD,¶ Miriam Lichtner, MD,# Alessandra Bandera, MD,k
Cristina Mussini, MD,** Enrico Girardi, MSC,†† Antonella d’Arminio Monforte, MD,† and
Alessandro Cozzi-Lepri, MSC,‡‡ on behalf of the ICONA Foundation Study Group
Background: The aim of the study was to quantify the risk of a drop
in CD4+ counts below 200 cells/mL after reaching values.350 cells/mL
on antiretroviral therapy (ART) (or after starting ART with CD4+ count
.350 cells/mL) in the absence of virological failure.
Setting: Ambulatory care services, Italy.
Methods: Prospective cohort study of patients enrolled in the
ICONA Foundation Study cohort who started ART with .350
CD4+/mL or with #350 CD4+/mL and reached values .350 cells/
mL after virological suppression (VS, defined by 2 consecutive
viral loads #50 copies/mL). The date of CD4 count .350 was the
baseline for the analysis and those with $1 viral load and CD4+
count after baseline were included. The primary end point was the
cumulative risk (estimated using the Kaplan–Meier method) of
a CD4+ drop below 200 cells/mL over follow-up, which was
censored at the date of virological failure (confirmed HIV-RNA
.50 copies/mL), death, or last visit.
Results: Six thousand six hundred sixty-three patients were included.
A confirmed CD4+ drop below 200 cells/mL was never observed over
a median follow-up of 45 (Q1: 21, Q3: 89) months, as long as VS was
maintained. Upper limits of the 97.5% confidence interval of rates of
confirmed CD4+ drop below 200 cells/mL were 0.28 and 0.38/1000
person-years of follow-up for patients with#350 and.350 CD4+ cells/
mL at starting ART.
Conclusions: In patients who started ART in Italy with .350 CD4+
cells/mL or reached .350 CD4+ cells/mL after VS, the risk of a CD4+
drop below 200 cells/mL in those maintaining VS was negligible.
Key Words: CD4+ cells count, CD4+ count dipping, CD4+ count
monitoring, virological suppression, antiretroviral therapy
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INTRODUCTION
CD4+ T-lymphocyte count is the strongest predictor of
disease progression in HIV-infected patients, and prophylaxis
of opportunistic infection is recommended when it drops
below 200 cells/mL.1–6 Frequent CD4+ cell count monitoring
has been highly recommended for many years, but the utility
of monitoring has been recently debated.7,8 In HIV-infected
people receiving antiretroviral therapy (ART), CD4+ counts
tend to increase or remain stable as long as viral replication is
controlled,9–12 and clinical events very infrequently occur
after ART introduction.10,13 Furthermore, there are no
treatment strategies to increase CD4+ cell count during
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periods of viral suppression. A CD4+ count drop below 200
cells/mL is currently seldom observed during successful
ART,14–17 and frequent testing may cause unnecessary
anxiety in patients with clinically inconsequential fluctua-
tions. Therefore, the utility of their monitoring has become
a matter of debate.7,8,17 Indeed, the treatment decision
a clinician can take in response to CD4+ monitoring is to
start (or restart) prophylaxis of opportunistic infections when
counts drop below 200 cells/mL1–4 or, in clinical settings
where viral load testing is not routinely implemented, to
prescribe viral load testing.18 In this context, some guidelines
recommend optional or stop monitoring CD4+ cell counts
once virological suppressions (VS) are sustained, and the
immunological status is stabilized.1,3,18
There are no randomized comparisons of individuals
following different CD4+ count monitoring strategies as they
are difficult to be performed, and although it is well
established that CD4+ cells falling below 200 cells/mL occur
infrequently while viral load is suppressed,14–17,19 robust
estimates of CD4+ cells dropping below 200 cells/mL over
long follow-up are limited. Furthermore, relevant differences
might emerge when comparing data collected in countries
with different organizations of the social health system.
The aim of this analysis was to quantify the probability
of a drop in CD4+ counts below 200 cells/mL after reaching
values .350 cells/mL on ART (or when starting ART with
CD4+ count .350 cells/mL) in the absence of virological
failure (VF), in a cohort of Italian HIV-infected patients.
METHODS
The ICONA Foundation Study (ICONA) is a multicen-
ter prospective observational study of HIV-1–infected adult
patients, which was set up in 1997. Eligible patients are those
starting ART when they are naive to antiretrovirals, regardless
of the reason. The ICONA Foundation Study has been
approved by IRB of all the participating centers; sensitive
data from patients are seen only in aggregate form. All pa-
tients signed a consent form to participate in ICONA, in
accordance with the ethical standards of the committee on
human experimentation and the Helsinki Declaration (1983
revision). Demographic, clinical and laboratory data, and
information on therapy are collected for all participants and
recorded using electronic data collection [www.icona.org].
CD4+ monitoring in cohort participants is performed at
least twice yearly, according to the study protocol and the
Italian guidelines.2 Antiretroviral regimens used by the
studied patients were not predefined by the study protocol
(which is strictly observational) but were prescribed accord-
ing to the current Italian guidelines.2
VS was defined as having achieved on 2 consecutive
occasions a viral load #50 copies/mL. Participants could be
included in this analysis if they belonged to 2 distinct inclusion
criteria group: first, participants who started ART with a CD4+
count .350 cells/mL; second, participants who started ART
with#350 CD4+/mL, achieved VS on therapy and whose CD4+
count subsequently increased to a value .350 cells/mL. In
patients who started ART with .350 CD4+/mL, baseline was
defined as the date of VS after at least 6 months since initiation
of ART. In those who started ART with #350 CD4+/mL,
baseline was the date of first achieving a CD4+ value .350
CD4+/mL after VS. For both groups, we insisted on people to
have at least 1 VL and CD4+ count assessed after baseline.
Viral load was assessed in each center according to
local procedures. Yearly change in CD4+ cell counts after
baseline were estimated by fitting a linear mixed model with
random intercept and slope.
The primary end point was the cumulative risk of
a confirmed CD4+ drop below 200 cells/mL over follow-up,
defined as 2 consecutive counts below 200 cells/ml (confirmed
drop). We also evaluated a secondary end point defined using
a single count below 200 cells/mL (unconfirmed drop).
Participants’ time at risk was censored at the date of VF
(defined as a confirmed HIV-RNA .50 copies/mL), death, or
last clinical visit. The Kaplan–Meier method was used to
estimate the cumulative risk of CD4+ dropping below 200
cells/mL over time. The 97.5% upper limit of the confidence
interval (CI) was calculated using a normal approximation.
All analyses were repeated also using an alternative definition
of viral rebound (with a cutoff of 400 copies/mL instead of
50 copies/mL).
All analyses were performed using SAS version 9.4
(SAS Institute, Cary, NC).
RESULTS
Six thousand six hundred sixty-three adult patients were
included in the analysis (Table 1). The main differences
between patients who started ART with ,350 CD4+/mL and
those who started ART with .350 CD4+/mL regarded sex,
risk factor, nationality, CD4+ nadir, CD4+/CD8+ ratio,
hepatitis C virus co-infection, and HIV-RNA load.
Over a median (Q1, Q3) follow-up of 45 (21, 89)
months, new AIDS-defining events occurred in 124 (2%)
patients, serious non-AIDS defining20 in 306 (5%), death in
153 (2%; 21 AIDS related, 132 non-AIDS related), and VF in
1796 (27%). The median (Q1, Q3) CD4+ count at the time the
AIDS-defining events occurred was 458 (228, 671) cells/mL.
The median (interquartile range) CD4+ measurements
over follow-up was 5 (2, 12), for an average of 2.6 (2.0,
3.4) measurements per year, and the median of prospective
HIV-RNA measurements was also 5 (2, 11), for 2.6 (2.0,
3.4) measurements per year.
Baseline CD4+ cell count was 646 (611, 682)/mL in
patients who started ART with #350 CD4+/mL and 757 (708,
807)/mL in those who started ART with .350 CD4+/mL
[difference: 110.9 (95% CI: 50.4 to 171.5) cells/mL; P ,
0.001]. Estimated yearly changes in CD4+ cell counts were
+27.44 (-18.2, +73.12) cells/mL in patients who started ART
with #350 CD4+/mL and +31.99 (-8.83, +72.81) cells/mL in
those who started ART with .350 CD4+/mL [difference:
+4.55 (-56.5, +65.64) cells/mL; P = 0.884] (Supplemental
Digital Content Figure, http://links.lww.com/QAI/B72).
A confirmed CD4+ drop below 200 cells/mL was never
observed over the time of the study; unconfirmed CD4+ drops
below 200 cells/mL occurred in 9 patients, and no clinical
events were observed at the time of occurrence. The Kaplan–
Meier estimate of the cumulative risk of unconfirmed drop
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below 200 cells/mL was 0.24% (95% CI: 0.07 to 0.40) by 4
years from baseline; no further events were observed over the
following 9 years, and 249 individuals were still at risk by 12
years after baseline. Upper limits of the 97.5% CI of rates of
confirmed CD4+ drop below 200 cells/mL were 0.28 and 0.38/
1000 person-years of follow-up (PYFU) for patients with
#350 and .350 CD4+ cells/mL at ART start, respectively.
Upper limits of the 97.5% CI of rates of confirmed CD4+ drop
TABLE 1. Main Characteristics of Patients at Starting Antiretroviral Therapy, by Baseline CD4+ Count Group
Characteristic
CD4+ Cell Count at Starting ART
.350 cells/mL (N = 2790) #350 cells/mL (N = 3873) P* Total (N = 6663)
Age, yrs, median (Q1, Q3) 39 (33, 46) 40 (34, 46) 0.092 40 (34, 46)
Female sex, n (%) 609 (21.8) 990 (25.6) ,0.001 1599 (24.0)
Mode of HIV transmission, n (%) ,0.001
Injection drug user 403 (14.5) 773 (20.0) 1176 (17.7)
Homosexual contacts 1239 (44.5) 1234 (32.0) 2473 (37.2)
Heterosexual contacts 993 (35.6) 1617 (41.8) 2610 (39.2)
Other/unknown 149 (5.4) 237 (6.1) 386 (5.8)
Non-Italian nationality, n (%) 292 (10.5) 523 (13.5) ,0.001 815 (12.2)
HBsAg, n (%) 0.806
Negative 2203 (79.0) 3047 (78.7) 5250 (78.8)
Positive 111 (4.0) 146 (3.8) 257 (3.9)
Not tested 476 (17.1) 680 (17.6) 1156 (17.3)
HCV Ab, n (%) ,0.001
Negative 1908 (68.4) 2469 (63.7) 4377 (65.7)
Positive 465 (16.7) 802 (20.7) 1267 (19.0)
Not tested 417 (14.9) 602 (15.5) 1019 (15.3)
Detectable CMV Ab, n (%) 1295 (46.4) 1834 (47.4) 0.449 3129 (47.0)
Calendar year of baseline, median (Q1, Q3) 2012 (2004, 2014) 2009 (2002, 2012) ,0.001 2010 (2003, 2013)
AIDS diagnosis, n (%) 128 (4.6) 760 (19.6) ,0.001 888 (13.3)
CD4+ count nadir, cells/mL, median (Q1, Q3) 402 (350, 484) 208 (105, 276) ,0.001 284 (177, 381)
CD4+ count, cells/mL, median (Q1, Q3) 670 (547, 848) 425 (384, 490) ,0.001 490 (407, 659)
CD8+ count, cells/mL, median (Q1, Q3) 947 (702, 1260) 940 (681, 1281) 0.669 944 (687, 1270)
CD4+/CD8+ ratio #0.3, n (%) 95 (3.6) 617 (16.6) ,0.001 712 (11.2)
HIV-RNA at ART start, log10 copies/mL,
median (Q1, Q3)
4.40 (3.58, 4.95) 4.82 (4.19, 5.33) ,0.001 4.65 (3.96, 5.17)
Antiretroviral started, n (%)
Zidovudine 525 (18.8) 1003 (25.9) ,0.001 1528 (22.9)
Lamivudine 985 (35.3) 1698 (43.8) ,0.001 2683 (40.3)
Abacavir 339 (12.2) 402 (10.4) 0.023 741 (11.1)
Tenofovir 1688 (60.5) 1927 (49.8) ,0.001 3615 (54.3)
Emtricitabine 1577 (56.5) 1764 (45.5) ,0.001 3341 (50.1)
Efavirenz 697 (25.0) 910 (23.5) 0.162 1607 (24.1)
Nevirapine 203 (7.3) 286 (7.4) 0.867 489 (7.3)
Rilpivirine 397 (14.2) 159 (4.1) ,0.001 556 (8.3)
Lopinavir/ritonavir 189 (6.8) 443 (11.4) ,0.001 632 (9.5)
Atazanavir/ritonavir 379 (13.6) 521 (13.5) 0.876 900 (13.5)
Darunavir/ritonavir 330 (11.8) 470 (12.1) 0.703 800 (12.0)
Raltegravir 122 (4.4) 179 (4.6) 0.629 301 (4.5)
ART type, n (%) ,0.001
2 NRTIs+ NNRTI 1404 (50.3) 1390 (35.9) 2794 (41.9)
2 NRTIs+ PI 450 (16.1) 924 (23.9) 1374 (20.6)
2 NRTIs+ PI/r 564 (20.2) 861 (22.2) 1425 (21.4)
2 NRTIs+ InSTI 137 (4.9) 119 (3.1) 256 (3.8)
Other 509 (18.2) 817 (21.1) 1326 (19.9)
*Chi-square or Kruskal–Wallis test as appropriate.
CMV Ab, antibodies anti–cytomegalovirus; HBsAg, hepatitis B surface antigen; HCV Ab, antibodies anti–hepatitis C virus; InSTI, integrase strand transfer inhibitor;
NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI/r, protease inhibitor boosted with ritonavir; PI, unboosted
protease inhibitor.
J Acquir Immune Defic Syndr  Volume 76, Number 4, December 1, 2017 CD4+ Drops Below 200 Cells/mL on ART
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. www.jaids.com | 419
Copyright  2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
below 200 cells/mL according to type of ART started,
hepatitis C virus co-infection, calendar year of baseline,
baseline CD4/CD8 .0.3 or #0.3, and time from HIV
diagnosis and HIV-RNA at ART start . or #5 log10
copies/mL are shown in Table 2. Of note, all these upper
limits were below 2.0 per 1000 PYFU. Only patients with
calendar year baseline between 1997 and 2001 and those with
a CD4+/CD8+ #0.3 at ART start had an upper limit that was
.1 per 1000 PYFU. Results were similar when viral rebound
was defined using the more conservative threshold of 400
copies/mL for the definition of VF (data not shown).
DISCUSSION
We investigated the risk of CD4+ drop below 200 cells/
mL in patients who started ART with .350 CD4+ cells/mL or
reached .350 CD4+ cells/mL after VS, and no events drop
was observed over a median follow-up of approximately 4
years, as long as VS was maintained. Even in the worst case
scenario, in which the true value for the incidence is equal to
the upper limit of the 97.5% of the CI, this incidence of a drop
,200 cells/mL was between 1 and 2 per 1000 PYFU. This
estimate is consistent with that previously found elsewhere. In
another analysis of a cohort of 1820 HIV-infected patients,
those with HIV-1 RNA ,200 copies/mL and CD4+ counts
$300 cells/mL had a 97% probability of maintaining durable
CD4+ counts $200 cells/mL for 4 years.14 Similarly, in the
ARTEMIS trial, only 1% of 449 patients with sustained HIV-
1 RNA suppression below 400 copies/mL experienced
a CD4+ count drop below 200 cells/mL on 2 consecutive
visits.15 In 7250 patients in South Africa, after 10 years of
ART, 93% of patients with ongoing VS maintained CD4+ cell
counts continuously above 200 cells/mL.19 Furthermore, in an
Asian cohort, among 1538 patients virologically suppressed
over an unreported duration of follow-up, the rate of
a confirmed drop below 200 CD4+/mL was 0.77/100
person-years. There was no significant difference in the time
to a confirmed drop below 200 CD4+/mL when comparing
people who were monitored biannually vs. those who had
annual CD4+ measurements.21 Finally, in the PISCIS Cohort
Study, over a median follow-up of almost 2 years, CD4+ cell
counts fell to ,200 cells/mL in 7% of 8695 patients.16
However, this estimate was calculated counting also single
measurements below 200 CD4+/mL.
It can be argued that experiencing a CD4+ count drop
below 200 cells/mL might not be clinically relevant, because
clinical events typically occur also with counts of .200 cells/
mL. Of interest, nevertheless, in 39,283 HIV-infected patients
with VL ,1000 copies/mL or CD4+ cell counts $350/mL in
the resource-limited setting, the implementation of routine
CD4+ cell count monitoring beyond 12 months after ART
initiation did not seem to have an impact on long-term
mortality rates.13
It needs to be considered that frequent monitoring of
CD4+ count in the setting of well-controlled viral replication
might be only a source of patients’ anxiety as the result of the
test is unlikely to trigger treatment decision7,8; reducing the
frequency of CD4+ monitoring might also reduce the overall
costs related to care of HIV-infected patients.8,17 However,
knowing when CD4+ drop below 200 cells/mL is important,
because in these cases (re)starting prophylaxis of opportunis-
tic infections is recommended.1–4 In the absence of random-
ized comparisons of CD4+ count monitoring strategies, our
analysis provides solid estimates that should help designing
such studies.
Caniglia et al recently tried to emulate a trial comparing
the effect of different frequencies of CD4+ cell counts
monitoring for clinical outcome using the data of a very
large cohort. Most of the 39,029 cohort participants who were
eligible for the comparison changed strategy during follow-up
(mostly in the first 6 months); indeed, less than 1/10 of them
did not change the initial strategy and could be maintained in
the analysis over 2 years of follow-up, thus largely limiting
the power of the study.10
The results of our analysis confirm and expand, over
a long follow-up and in a setting where there is universal
access to treatment, the results of previous analyses. They
also lend support to optional monitoring of CD4+ cell counts
in patients with satisfactory virological and immunological
response to ART.
As participants’ follow-up time was censored at VF, the
results of this study are applicable only to the population of
HIV-infected individuals with current stable VS. It must be
noted that results also do not apply to immunological
nonresponders. Indeed, people who started ART with #350
TABLE 2. CD4+ Cell Drop Rates (per 1000 PYFU) and
Respective 1-Sided Upper Limit of 97.5% CI
Stratification Factors





CD4+ cell count at ART start
0–350/mL 0 13,306 0.28
.350/mL 0 9721 0.38
Type of ART
PI-based ART 0 5135 0.72
NNRTI-based ART 0 9297 0.40
Other ART 0 4752 0.78
HCV co-infection
Absent 0 4734 0.78
Present 0 15,145 0.24
Year of baseline
1997–1999 0 2059 1.80
2000–2001 0 2318 1.59
2002–2006 0 6768 0.55
.2007 0 11,883 0.31
CD4+/CD8+
0–0.3 0 2537 1.45
.0.3 0 19,766 0.19
HIV-RNA at ART start,
log10 copies/mL
0–5 0 15,640 0.24
.5 0 6921 0.53
Total 0 22,561 0.16
HCV, hepatitis C virus; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI,
protease inhibitor.
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CD4+/mL and never attained values .350 cells/mL were
excluded from the analysis because less frequent CD4+ cell
counts monitoring is not an option in these patients.
The main limitations of this study are the relatively
small sample size and the relatively short duration of follow-
up; however, all events occurred over the first 3 years, so it is
unlikely that results will be different by repeating the analysis
after waiting for further follow-up to cumulate.
In summary, in patients who started ART in Italy with
.350 CD4+ cells/mL, or reached .350 CD4+ cells/mL after
VS, with a stable controlled viral suppression, a confirmed
CD4+ drop below 200 cells/mL was never observed over an
average of 4 years. The results of this study support optional
monitoring of CD4+ cell counts, in a setting in which viral
load assessment is easily available and in patients with these
characteristics; they are also useful to help designing
randomized trials comparing CD4+ count monitoring strate-
gies in virologically suppressed populations.
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